A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).

Sehouli, J., Tomè, O., Dimitrova, D., Camara, O., Runnebaum, I.B., Tessen, H.W., Rautenberg, B., Chekerov, R., Muallem, M.Z., Lux, M.P., Trarbach, T., Gitsch, G., 2016.

J. Cancer Res. Clin. Oncol. 143(3), 541–550. doi:10.1007/s00432-016-2307-0

Studie: Treosulfan-Studie; Indikation: Sonstige; Jahr: 2016; Veranstaltung: -; Journal: Journal of Cancer Research and Clinical Oncology

Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com